Nike Stock News

Nike's push into the booming outdoor recreation market — which will kick off on Monday with the launch of a new trail running shoe — will test whether it can turn a little-known sub-brand into a meaningful growth engine.

Nike is rebounding with a new CEO, improved tariff clarity, and a focus on core strengths, despite mixed retail sector earnings. Q4 earnings beat expectations, and technical indicators point to a bullish setup, with a potential breakout target near $108 per share. Valuation remains attractive, as shares trade below historical averages, offering about 10% upside to normalized fair value.

Despite near-term EPS headwinds and China/wholesale uncertainty, I reiterate my Buy rating on Nike for long-term investors. Short-term challenges, including tariffs and negative EPS revisions, are likely temporary. Nike's strong ROCE and reinvestment rates support double-digit long-term growth even under my more conservative projections.

Knight and his wife are making a record private gift to Oregon Health & Science University amid broader battles over public funding for higher education.

The Knight Foundation said the gift that will be used to shift the scientific approach to cancer treatment, research and patient care outcomes.

Nike co-founder Phil Knight is donating $2 billion to the Oregon Health and Science University's Cancer Institute. The Knight Foundation says it's the single largest donation ever to a U.S. university, college or health institution.

Nike (NKE 3.16%) and Lululemon (LULU 3.91%) face higher tariffs, as they import most of their products.

JD Sports Fashion PLC (LSE:JD.) has long ridden in Nike's slipstream.